US Patent

US11065213 — Amantadine compositions and preparations thereof

Formulation · Assigned to Adamas Pharma LLC · Expires 2038-08-23 · 12y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects oral pharmaceutical compositions of amantadine, including extended release forms, with reduced gastrointestinal side effects and sleep disturbances.

USPTO Abstract

Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.

Drugs covered by this patent

Patent Metadata

Patent number
US11065213
Jurisdiction
US
Classification
Formulation
Expires
2038-08-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Adamas Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.